U.S. Radiation Oncology Market Size & Outlook, 2026-2033
Global Market
Related Markets
U.S. radiation oncology market highlights
- The U.S. radiation oncology market generated a revenue of USD 5,804.7 million in 2025 and is expected to reach USD 13,677.0 million by 2033.
- The U.S. market is expected to grow at a CAGR of 11.4% from 2026 to 2033.
- In terms of segment, external beam radiation therapy (ebrt) was the largest revenue generating treatment type in 2025.
- Systemic Targeted Radiation Therapy is the most lucrative treatment type segment registering the fastest growth during the forecast period.
Radiation oncology market data book summary
| Market revenue in 2025 | USD 5,804.7 million |
| Market revenue in 2033 | USD 13,677.0 million |
| Growth rate | 11.4% (CAGR from 2026 to 2033) |
| Largest segment | External beam radiation therapy (ebrt) |
| Fastest growing segment | Systemic Targeted Radiation Therapy |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | External Beam Radiation Therapy (EBRT), Internal Beam Radiation Therapy, Systemic Targeted Radiation Therapy |
| Key market players worldwide | Siemens Healthineers AG ADR, Elekta AB ADR, BD, Accuray Inc, IBA RadioPharma Solutions, IsoRay, MeVis Medical Solutions AG, Nordion, Ntp Radioisotopes, Curium Pharma, ViewRay |
Other key industry trends
- In terms of revenue, U.S. accounted for 41.4% of the global radiation oncology market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. radiation oncology market is projected to lead the regional market in terms of revenue in 2033.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 13,677.0 million by 2033.
As per the American Cancer Society, in the U.S., 1,762,450 new cancer cases are estimated to be diagnosed and 606,880 people are expected to die from cancer in 2019. Cancer is the second most common cause of death in the U.S. Rising collaborations among organizations to improve the quality of care for people living with cancer are among the major factors driving the market growth in this country.
In January 2018, ASTRO collaborated with American Society of Clinical Oncology (ASCO) to launch a new registry Qualified Clinical Data Registry (QCDR). This registry tracks the quality of medical care provided to patients undergoing cancer treatment and also makes it easier for radiation and medical oncologists to report quality-related performance metrics needed by the Federal government.
No credit card required*
Publish Date: Mar 26, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Radiation Oncology Market Scope
Radiation Oncology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Siemens Healthineers AG ADR | View profile | 71,400 | Siemensstr. 3, Forchheim, BY, Germany, 91301 | www.siemens-healthineers.com |
| BD | View profile | 10001+ | Franklin Lakes, New Jersey, United States, North America | www.bd.com |
| Elekta AB ADR | View profile | 4,584 | Kungstensgatan 18, Box 7593, Stockholm, Sweden, SE-103 93 | www.elekta.com |
| IsoRay | View profile | 51-100 | Richland, Washington, United States, North America | isoray.com/ |
| Accuray Inc | View profile | 1,024 | 1240 Deming Way, Madison, WI, United States, 53717 | www.accuray.com |
| IBA RadioPharma Solutions | View profile | 1001-5000 | Louvain-la-neuve, Vlaams-Brabant, Belgium, Europe | www.iba-radiopharmasolutions.com/ |
| MeVis Medical Solutions AG | View profile | 101-250 | Bremen, Bremen, Germany, Europe | www.mevis.de/ |
| Nordion | View profile | 251-500 | Kanata, Ontario, Canada, North America | nordion.com |
| Ntp Radioisotopes | View profile | 251-500 | Brits, NA - South Africa, South Africa, Africa | www.ntp.co.za/ |
| Curium Pharma | View profile | 1001-5000 | Paris, Ile-de-France, France, Europe | www.curiumpharma.com/contact/ |
U.S. Radiation Oncology Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Radiation Oncology Market Outlook will help companies and investors design strategic landscapes.
External Beam Radiation Therapy (Ebrt) was the largest segment with a revenue share of 79.58% in 2025.
Horizon Databook has segmented the U.S. radiation oncology market based on external beam radiation therapy (ebrt), internal beam radiation therapy, systemic targeted radiation therapy covering the revenue growth of each sub-segment from 2021 to 2033.
As per the American Cancer Society, in the U.S., 1,762,450 new cancer cases are estimated to be diagnosed and 606,880 people are expected to die from cancer in 2019. Cancer is the second most common cause of death in the U.S. Rising collaborations among organizations to improve the quality of care for people living with cancer are among the major factors driving the market growth in this country.
In January 2018, ASTRO collaborated with American Society of Clinical Oncology (ASCO) to launch a new registry Qualified Clinical Data Registry (QCDR). This registry tracks the quality of medical care provided to patients undergoing cancer treatment and also makes it easier for radiation and medical oncologists to report quality-related performance metrics needed by the Federal government.
- U.S. Radiation Oncology Market Treatment Type Outlook (Revenue, USD Million , 2021-2033)
- External Beam Radiation Therapy (EBRT)
- Internal Beam Radiation Therapy
- Systemic Targeted Radiation Therapy
- U.S. Radiation Oncology Market Technology Outlook (Revenue, USD Million , 2021-2033)
- Image-Guided Radiotherapy (IGRT)
- Intensity-Modulated Radiotherapy (IMRT)
- Volumetric Modulated Arc Therapy (VMAT)
- 3D Conformal Radiation Therapy (3D-CRT)
- Stereotactic Radiotherapy (SRS / SBRT)
- Proton Beam Delivery Technology
- Heavy-Ion Delivery Technology
- Adaptive Radiotherapy
- Upright Beam Delivery Technology
- U.S. Radiation Oncology Market Application Outlook (Revenue, USD Million , 2021-2033)
- External Beam Radiation Therapy (EBRT)
- Internal Beam Radiation Therapy
- Radioligand Therapy Applications
- U.S. Radiation Oncology Market Target Customer Outlook (Revenue, USD Million , 2021-2033)
- Academic & Research Cancer Centers
- Government & Public Tertiary Hospitals
- Private Oncology Chains
- Specialty Proton / Particle Therapy Centers
- Nuclear Medicine & Theranostics Centers
Reasons to subscribe to Radiation Oncology Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Radiation Oncology Market Outlook databook
- Our clientele includes a mix of Radiation Oncology Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Radiation Oncology Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Radiation Oncology Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Radiation Oncology Market, 2021-2033 (US$M)
U.S. radiation oncology market statistics, by treatment type, 2021-2033 (US$M)
